Leerink reiterated an Outperform rating and $24 price target on Regenxbio (RGNX) after Sarepta (SRPT) announced a Duchenne muscular dystrophy patient treated with Elevidys has died from acute liver failure. While the firm does not see this news impacting the total addressable market for DMD, the event further opens the door for Regenxbio to differentiate their risk/benefit profile, the analyst tells investors in a research note. The firm said this view is based on encouraging efficacy to date, the use of a different adeno-associated virus capsid and transgene versus Elevidys, and a clean safety profile to date, with no drug-induced liver injury reported in the 11 patients treated so far.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- Analysts remain optimistic about Elevidys after Sarepta reports patient death
- Leerink says Sarepta stock reaction ‘overdone,’ remains positive on Elevidys
- Regenxbio price target lowered to $34 from $36 at H.C. Wainwright
- RegenXBio’s Strategic Advancements and Financial Stability Highlighted in Analyst Recommendation
- REGENXBIO Earnings Call Highlights Strategic Progress